Wedbush Expects Weaker Earnings for Spyre Therapeutics

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Stock analysts at Wedbush lowered their Q1 2025 earnings estimates for shares of Spyre Therapeutics in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their prior forecast of ($0.84). Wedbush currently has a "Outperform" rating and a $45.00 price target on the stock. The consensus estimate for Spyre Therapeutics' current full-year earnings is ($4.89) per share. Wedbush also issued estimates for Spyre Therapeutics' Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($2.83) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.98) EPS.

A number of other analysts have also commented on SYRE. Guggenheim boosted their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 25th. Robert W. Baird lifted their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Spyre Therapeutics has a consensus rating of "Buy" and an average price target of $48.57.

Spyre Therapeutics Stock Performance

NASDAQ:SYRE traded down $2.07 during mid-day trading on Friday, hitting $29.20. The company had a trading volume of 394,556 shares, compared to its average volume of 510,974. Spyre Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $47.97. The firm has a market cap of $1.50 billion, a P/E ratio of -3.91 and a beta of 2.90. The business's fifty day moving average is $31.34 and its two-hundred day moving average is $30.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank purchased a new position in Spyre Therapeutics in the 2nd quarter worth approximately $28,000. Quest Partners LLC bought a new stake in Spyre Therapeutics in the second quarter worth $36,000. SG Americas Securities LLC purchased a new stake in shares of Spyre Therapeutics during the second quarter valued at approximately $130,000. Intech Investment Management LLC purchased a new stake in shares of Spyre Therapeutics during the third quarter valued at $246,000. Finally, Carlyle Group Inc. purchased a new position in shares of Spyre Therapeutics in the 2nd quarter worth $227,000. Institutional investors own 80.39% of the company's stock.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).